- JP-listed companies
- Balance sheet
(4893) Balance sheet
Market cap
¥6.4B
P/E ratio
Develops cancer immunotherapy treatments for solid tumors using proprietary PRIME technology that enhances immune cell activation and generates revenue through both in-house drug development and technology licensing.
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Cash and cash equivalents | - | 4,141 | 4,521 | 5,556 | 4,671 | 3,918 |
| Total current assets | - | 4,225 | 4,584 | 5,717 | 4,775 | 3,983 |
| Total non-current assets | - | 46 | 57 | 62 | 25 | 28 |
| Total assets | - | 4,271 | 4,641 | 5,779 | 4,800 | 4,012 |
| Total current liabilities | - | 80 | 335 | 86 | 69 | 74 |
| Total non-current liabilities | - | 5 | 5 | 5 | 5 | 5 |
| Total liabilities | - | 86 | 340 | 91 | 75 | 80 |
| Retained earnings | - | -873 | -1,259 | -2,389 | -3,354 | -4,147 |
| Stockholders' equity | 2,598 | 4,185 | 4,301 | 5,687 | 4,725 | 3,932 |